Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham Heart Study beyond LDL-C and non-HDL-C

Abstract

Aims

Analyses using conventional statistical methodologies have yielded conflicting results as to whether low-density lipoprotein cholesterol (LDL-C) or non-high-density lipoprotein cholesterol (non-HDL-C) or apolipoprotein B (apoB) is the best marker of the apoB-associated risk of coronary heart disease. The aim of this study was to determine the additional value of apoB beyond LDL-C or non-HDL-C as a predictor of coronary heart disease.

Methods and results

For each patient from the Framingham Offspring Cohort aged 40–75 years (n = 2966), we calculated the extent to which the observed apoB differed from the expected apoB based on their LDL-C or non-HDL-C. We added this difference to a Cox model predicting new onset coronary heart disease over a maximum of 20 years adjusting for standard risk factors plus LDL-C or non-HDL. The difference between observed and expected apoB over LDL-C or non-HDL-C was highly prognostic of future coronary heart disease events: adjusted hazard ratios 1.26 (95% confidence interval: 1.15, 1.37) and 1.20 (1.11, 1.29), respectively, for each standard deviation increase beyond expected apoB levels. When this difference between observed and expected apoB was added to standard coronary heart disease prediction models including LDL-C or non-HDL-C, prediction improved significantly (likelihood ratio test p-values <0.0001) and discrimination c-statistics increased from 0.72 to 0.73. The corresponding relative integrated discrimination improvements were 11% and 8%, respectively.

Conclusions

apoB improves risk assessment of future coronary heart disease events over and beyond LDL-C or non-HDL-C, which is consistent with coronary risk being more closely related to the number of atherogenic apoB particles than to the mass of cholesterol within them.

Keywords

Risk factor non-HDL-C apoB CAD discordance risk prediction guidelines

Get full access to this article

View all access options for this article.

References

Tabas

Williams

Boren

. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: Update and therapeutic implications. Circulation 2007; 116: 1832–1442.

Barter

Ballantyne

Carmena

. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: Report of the thirty-person/ten-country panel. J Intern Med 2006; 259: 247–258.

Krauss

Burke

. Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res 1982; 23: 97–104.

Teng

Thompson

Sniderman

. Composition and distribution of low density lipoprotein fractions in hyperapobetalipoproteinemia, normolipidemia, and familial hypercholesterolemia. Proc Natl Acad Sci U S A 1983; 80: 6662–6666.

Chapman

Laplaud

Luc

. Further resolution of the low density lipoprotein spectrum in normal human plasma: Physicochemical characteristics of discrete subspecies separated by density gradient ultracentrifugation. J Lipid Res 1988; 29: 442–458.

Sniderman

St-Pierre

Cantin

. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. Am J Cardiol 2003; 91: 1173–1177.

Ingelsson

Schaefer

Contois

. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA 2007; 298: 776–785.

Friedewald

Levy

Fredrickson

. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.

Cox

. Regression models and life tables. J R Stat Soc B 1972; 34: 187–220.

10.

Pencina

D’Agostino

. Overall C as a measure of discrimination in survival analysis: Model specific population value and confidence interval estimation. Stat Med 2004; 23: 2109–2123.

11.

Pencina

D’Agostino

Sr D’Agostino

Jr . Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157–172; discussion 207–212.

12.

Demler

Pencina

D’Agostino

Sr . Misuse of DeLong test to compare AUCs for nested models. Stat Med 2012; 31: 2577–2587.

13.

Vickers

Cronin

Begg

. One statistical test is sufficient for assessing new predictive markers. BMC Med Res Methodol 2011; 11: 13–13.

14.

SAS/STAT 9.2 user’s guide, Chapter 3: Introduction to statistical modeling with SAS/STAT software. [S.l.]. Cary, NC: SAS, 2008.

15.

Pencina

D’Agostino

Pencina

. Interpreting incremental value of markers added to risk prediction models. Am J Epidemiol 2012; 176: 473–481.

16.

Mora

Buring

Ridker

. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation 2014; 129: 553–561.

17.

Cromwell

Otvos

Keyes

. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study – implications for LDL management. J Clin Lipidol 2007; 1: 583–592.

18.

Otvos

Mora

Shalaurova

. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol 2011; 5: 105–113.

19.

Sniderman

Islam

Yusuf

. Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study. Atherosclerosis 2012; 225: 444–449.

20.

Koskinen

Magnussen

Würtz

. Apolipoprotein B, oxidized low-density lipoprotein, and LDL particle size in predicting the incidence of metabolic syndrome: The Cardiovascular Risk in Young Finns study. Eur J Prev Cardiol 2012; 19: 1296–1303.

21.

Di Angelantonio

Gao

Pennells

. Lipid-related markers and cardiovascular disease prediction. JAMA 2012; 307: 2499–2506.

22.

Sniderman

Williams

Contois

. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011; 4: 337–345.

23.

Ndumele

Matsushita

Astor

. Apolipoproteins do not add prognostic information beyond lipoprotein cholesterol measures among individuals with obesity and insulin resistance syndromes: The ARIC study. Eur J Prev Cardiol 2012; 21: 866–875.

24.

Contois

McConnell

Sethi

. Apolipoprotein B and cardiovascular disease risk: Position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2009; 55: 407–419.

25.

Sniderman

Couture

de Graaf

. Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. Nat Rev Endocrinol 2010; 6: 335–346.

26.

Sniderman

. Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: Implications for clinical practice. J Clin Lipidol 2008; 1: 36–42.

27.

Thanassoulis

Williams

. Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: A meta-analysis of randomized trials. J Am Heart Assoc 2014; 3: e000759–e000759.